How many ml is 7.5 mg of tirzepatide — and why it matters less than you think

Why volume is fixed and concentration carries the dose

People searching for the millilitre equivalent of a tirzepatide dose are often trying to verify their pen, understand what they're injecting, or reconcile a number they've seen elsewhere. The answer is straightforward: all six licensed strengths of Mounjaro (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) are presented in a 0.5 ml injection. What changes between strengths is the concentration of tirzepatide dissolved in that 0.5 ml, not the physical amount of liquid you inject.

This design is deliberate. The KwikPen is not adjustable. Press the button once and it delivers the full pre-set dose; there is nothing to calibrate, no markings to read, no syringe to fill. If you are curious about the 5 mg version of the pen, our guide to the 5 mg dose volume explains the same principle at that concentration. The Mounjaro Summary of Product Characteristics (published on the electronic Medicines Compendium (eMC) and the authoritative document for all prescribing and dispensing decisions) confirms the 0.5 ml volume across all strengths.

One quick habit worth building: when a new pen arrives, check the label confirms the strength your prescriber has authorised before you use it. It takes under a minute, and it matters more than knowing the millilitre figure.

Where 7.5 mg sits in the dose schedule, and who reaches it

Mounjaro is a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed in the UK for weight management. Treatment opens at 2.5 mg, a tolerability step whose job is to let your body adjust, not to produce meaningful weight loss. From there, the schedule typically moves in 4-week steps: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, with the prescriber deciding at each stage whether to increase, hold or review. You can read more about what that early stage looks like on our 2.5 mg dose page.

Reaching 7.5 mg means you have already completed at least two months on lower doses and that your prescriber is satisfied with your tolerance. That clinical checkpoint is what makes this a relatively settled part of treatment for most people. The NHS page on tirzepatide sets out the standard side-effect profile and what to watch for at any dose, the NHS tirzepatide medicines page is the clearest patient-level reference available.

Evidence from the SURMOUNT-1 trial, which enrolled thousands of adults with obesity over 72 weeks, showed average weight reductions of around 20–21% at the highest dose. Those results reflect the full titration sequence, including the intermediary steps like 7.5 mg, not a single dose in isolation. Each step builds on the last.

The decision most readers are actually facing

Searching for the volume of a specific dose usually signals one of a handful of real questions: Is this pen right? Am I on the right dose? Should I have moved up by now? Those are prescriber questions, not volume questions. A prescriber looks at your weight trend, your side-effect history and how long you have been at the current dose before recommending a change. The millilitre figure cannot tell you any of that.

If you are comparing the 7.5 mg step to the one above it, the 10 mg dose guide covers the same volume principle at the next concentration. And if you are interested in what the full 15 mg maintenance dose represents, that page puts the trial evidence in context.

For those wondering whether their dose corresponds to a certain number of insulin units (a question that comes up when people have previously used injectable medicines) our page on how many units 7.5 mg of tirzepatide equals addresses that directly. The short answer is that insulin-unit measurement does not apply to Mounjaro pens, but the full explanation is worth reading if the question has been on your mind.

Cost is sometimes part of the calculation at this stage of treatment too. The Eli Lilly price increase context page explains how UK list prices changed from September 2025 and what that means for private prescriptions.

What a prescriber considers beyond the dose number

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 and above where a weight-related condition such as hypertension, dyslipidaemia or obstructive sleep apnoea is present. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; the prescriber also reviews medical history, current medicines and whether lifestyle changes are in place alongside treatment.

Common side effects at any dose are gastrointestinal in character: nausea is the most frequently reported, typically peaking in the first week or two after a new dose and then settling. Constipation, loose stools and reflux are also reported. Serious but infrequent effects include acute pancreatitis, if you develop severe stomach pain that spreads to your back, seek urgent medical attention and report it via the MHRA Yellow Card service.

Pregnancy and breastfeeding are contraindications; if there is any chance of conception, discuss contraception with your prescriber before starting or increasing the dose. Tirzepatide is not licensed for anyone under 18.

Our clinical team at nume reviews every consultation personally, a named prescriber, not software, reads your answers the same day. If you are considering starting treatment or have questions about where you are in the titration schedule, the right place to begin is a clinical conversation. You can explore what that looks like on our weight-loss treatments page.